UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

AURIS MEDICAL HOLDING AG

(Name of Issuer)

Common Shares

(Title of Class of Securities)

H03579101

(CUSIP Number)

April 21, 2015

(Date of Event Which Requires Filing this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

¨ Rule 13d-1(b)

¨ Rule 13d-1(c)

x Rule 13d-1(d)

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1 of 8

Item 1

Bahnhofstrasse 21, 6300 Zug, Switzerland

Item 2

This Schedule 13G is being filed by Bellevue Asset Management AG and Oliver Kubli. The common shares of Auris Medical Holding AG reported in this Schedule 13G as beneficially owned by Bellevue Asset Management AG (the “Adamant Shares”) are held by Adamant Global Biotech, Adamant Global Generika, Adamant Global Medtech und Services, and ZKB Fonds Aktien Gesundheit (together, the “ZKB Funds”), each of which holds less than 5% of the common shares of shares in Auris Medical Holding AG. The ZKB Funds are managed by Bellevue Asset Management AG following the merger of Adamant Biomedical Investments AG with and into Bellevue Asset Management AG (the “Merger”) pursuant to which Bellevue Asset Management AG succeeded to Adamant Biomedical Investments AG’s interest in and to the ZKB Funds. Following the Merger, Bellevue Asset Management AG exercises dispositive power over the Adamant Shares, which are sponsored by Balfidor Fondsleitung AG, Balfidor Holding AG, and Zurcher Kantonalbank (together, the “Sponsors”), which exercise sole voting power over the Adamant Shares. Mr. Kubli is a Senior Portfolio manager for the ZKB Funds. He disclaims beneficial ownership of the Adamant Shares except to the extent of his pecuniary interest therein. The Sponsors are unrelated to both Bellevue Asset Management AG and Mr. Kubli.

The business address of both Bellevue Asset Management AG and Mr. Kubli is Freischuetzgasse 3, Zurich, Switzerland.

Bellevue Asset Management AG: Switzerland.

Oliver Kubli: Switzerland.

Item 3

If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

a. ¨ Broker or Dealer registered under Section 15 of the Act.

b. ¨ Bank as defined in Section 3(a)(6) of the Act.

c. ¨ Insurance company as defined in Section 3(a)(19) of the Act.

4 of 8

d. ¨ Investment company registered under section 8 of the Investment Company Act of 1940.

e. ¨ An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

f. ¨ An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

g. ¨ A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);

h. ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

i. ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;

j. ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ¨

N/A

5 of 8

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

N/A

N/A

N/A

6 of 8

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURES

After reasonable inquiry and the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

7 of 8

Exhibit A

Joint Filing Statement

We, the undersigned, hereby express our agreement that the attached Schedule 13G (including all amendments thereto) is filed on behalf of each of the undersigned.

8 of 8